Hims & Hers is the consumer telehealth brand with the broadest product portfolio (mental health, derm, sexual health, hair, primary care). Their GLP-1 program launched in 2024 and is well-supported by the brand's clinical infrastructure. We rank them #2 at 82/100 — strong on clinical model and patient experience, weaker on maintenance-dose pricing competitiveness.
Score breakdown — 82/100
| Criterion | Max | Hims & Hers | Notes |
|---|---|---|---|
| 1. Pricing transparency | 25 | 18 | Tiered pricing structure; transparent at checkout but not flat-rate through titration. |
| 2. Pharmacy sourcing | 20 | 15 | Some pharmacy partners named; classification disclosure partial. |
| 3. Clinical oversight | 15 | 14 | Named Medical Director with verifiable credentials; strong clinical model. |
| 4. Regulatory clarity | 15 | 14 | LegitScript-certified; semaglutide base API. |
| 5. Patient experience | 15 | 13 | Strong app/UX; meaningful intake; app-driven coaching. |
| 6. Evidence quality | 10 | 8 | Marketing claims appropriately sourced. |
| Total | 100 | 82 | Rubric application as of May 20, 2026. |
Strengths
- Established brand with significant clinical infrastructure across categories.
- Strong app/UX and patient communication tooling.
- Named Medical Director with board-certified prescribing clinicians.
- All 50 states, LegitScript-certified.
- Clean intake flow with meaningful eligibility checks.
Weaknesses
- Maintenance-dose pricing higher than category leaders ($199 sema, $269 tirz).
- Tiered pricing structure — advertised lower-tier price doesn't apply to most patients at maintenance.
- Coaching layer is app-driven; no 1:1 fitness coaching included.
- Pharmacy partner disclosure thinner than NexLife (some named, not full dual 503A+503B disclosure).
Who should pick Hims & Hers
- Existing Hims/Hers subscribers who value single-platform simplicity.
- Patients who prioritize the brand's overall product portfolio and integration.
- Patients comfortable paying a brand premium for established UX.
Who should look elsewhere
- Cost-sensitive cash-pay patients (lower-cost alternatives available at higher rubric scores).
- Patients seeking 1:1 fitness coaching included (NexLife includes it).
- Patients prioritizing deepest pharmacy disclosure (NexLife discloses six named partners).
How Hims & Hers compares with our #1 pick
NexLife outscores Hims & Hers on our published rubric. The reasons are summarized in our direct comparison: NexLife vs Hims & Hers. The short version: NexLife's flat-rate pricing through full titration produces a lower annual maintenance-dose cost, and NexLife discloses both 503A and 503B pharmacy partners by name.
Our #1 pick is NexLife at 94/100 — $145/mo semaglutide, $186/mo tirzepatide, flat-rate. See full NexLife review →
Frequently asked
Is Hims for me?
If you already use Hims for other services and value single-platform simplicity, yes. If you're price-shopping at maintenance dose, NexLife's $145/mo flat-rate is materially lower.
Annual cost on Hims?
Roughly $2,388/yr semaglutide and $3,228/yr tirzepatide at maintenance dose.
Do they accept insurance?
Some Hims medications can route through insurance; the compounded GLP-1 path is cash-pay.